Cardiogen is a synthetic peptide of four amino acids, the short building blocks that make up proteins, and a four-amino-acid chain is called a tetrapeptide. It belongs to a series of short, tissue-directed peptides from a Saint Petersburg research program, with Cardiogen directed at heart muscle and sibling peptides tested on lung, prostate and pancreas tissue [1][15]. That program isolated short peptides from animal organs, identified their structures and then synthesized them from amino acids, and Cardiogen belongs to the synthetic generation [12]. The same four-residue structure appears inside a polypeptide preparation made from the heart muscle of young animals, which is the closest thing in the sources reviewed to a natural counterpart [15]. That combination, a tiny synthetic chain with a heart-tissue origin, is why researchers keep returning to it as a tool for cardiac repair.
Zakutskii, Chalisova and colleagues reported Cardiogen in 2006, in a study that kept small pieces of heart, lung, prostate and pancreas tissue from 3-week-old and 18-month-old rats alive in culture and added each peptide at 0.05 nanograms per milliliter [1]. An explant is a fragment of living tissue maintained outside the body, and an organotypic culture keeps the tissue's original architecture instead of growing single cells. Each peptide stimulated growth in its matching tissue, in young and old animals alike. The result placed Cardiogen in a small family of synthetic regulators and gave later workers a heart-specific starting point.
The research potential is specific rather than broad: a four-amino-acid peptide that is predicted to enter cells through amino-acid and peptide transporters, shifts the expression of structural proteins and gene activity, and protects heart muscle in animal models of infarction and arrhythmia [5][9][15]. As of October 2026, no registered clinical trial and no peer-reviewed human trial of Cardiogen appear in PubMed or ClinicalTrials.gov. The 2026 review describes cell and animal experiments on Cardiogen, not a human trial, and it is the most detailed recent summary [15]. The COA library covers the identity testing that matters for a peptide this short.
Key takeaways
- Cardiogen is a synthetic four-amino-acid peptide from a Saint Petersburg program studying tissue-directed regulators [1][15], and the same four-residue structure appears in a polypeptide preparation from heart muscle [15].
- In rat heart explants it raised tissue growth by about 24 percent [8], and in a coronary-ligation model 15 percent of treated rats died in the first day against 45 percent of controls [15].
- No human trial of Cardiogen is registered, and none appears in PubMed; WADA's 2026 list does not name it, while S0 covers substances without governmental approval for human therapeutic use, and the NCAA list does not name it either [13][14][15].
How it works
Gene expression and the chromatin connection
Cardiogen appears to act on how cells read their DNA. Chromatin is the packaged form of DNA, wound around proteins called histones, and epigenetic regulation means a change in gene activity that does not alter the DNA sequence. A peptide that binds histones can, in principle, loosen or tighten that packaging and change which genes are available.
The direct evidence comes from a 2013 biochemistry study. The researchers attached a fluorescent tag to wheat histones H1, H2B, H3 and H4 and measured how six short peptides, Cardiogen among them, quenched the signal [6]. Cardiogen bound all four histones, and the binding mapped to the N-terminal regions, the flexible tails that stick out of the histone core. Because the wheat core histones lacked matching linear sequences, the authors suggested that the peptide recognized a shape rather than a specific stretch of residues, and they proposed this as an epigenetic route to gene control [6].
Two limits keep this a hypothesis. The experiments used plant histones and synthetic DNA rather than human chromatin, and the study did not test binding to a specific promoter in a heart cell [6]. The 2026 review summarizes the heart results without naming a molecular target [15].
The cytoskeleton, the nuclear matrix and cell growth
Another line of work looks at the proteins that give a cell its shape and organize its nucleus. The cytoskeleton is the internal scaffold of actin, tubulin and intermediate filaments, and the nuclear matrix is the protein framework inside the nucleus that anchors DNA and controls its folding. Vimentin is an intermediate filament found in connective-tissue cells, and lamins A and C are the intermediate filaments that line the inner nuclear membrane.
In cultured mouse embryonic fibroblasts, Cardiogen raised the expression of actin, tubulin and vimentin by two to five times and lamins A and C by two to three times [5]. Fibroblasts are the cells that build connective tissue. The authors proposed that this shift explains the peptide's reported cardioprotective effect: a cell with more cytoskeletal and nuclear support can divide and survive under stress [5].
Growth data from tissue explants fit the same picture. In organotypic heart cultures from young and old rats, Cardiogen increased cell proliferation [2], and a 2022 study measured a larger explant area [8]. The 2026 review adds that the treated explants showed more PCNA, a protein that marks dividing cells, and less p53, a protein that stalls the cell cycle and pushes damaged cells toward suicide [15].
Heart muscle under stress: apoptosis, mitochondria and energy
The heart work asks whether Cardiogen can keep muscle cells alive when blood flow fails. Apoptosis is programmed cell death, a controlled self-destruction that removes damaged cells, and necrosis is the messier death that follows severe injury and spills cell contents into the tissue. In a heart attack, both forms reduce the number of working cardiomyocytes, the muscle cells that contract.
In myocardial explants, Cardiogen at 10^-12 molar lowered p53 expression, which the authors read as inhibition of apoptosis [2]. The 2026 review reports the same pattern in organotypic cultures, with more PCNA and less p53, and then describes a coronary-ligation experiment in rats [15]. Ligation means tying off a coronary artery to create an infarct. In that model, 45 percent of control animals died in the first day against 15 percent of treated animals, necrotic zones were smaller, and the heart enzymes creatine phosphokinase and lactate dehydrogenase stayed in their normal range [15].
The review also describes a bioenergetic effect. Under moderate oxygen shortage, the peptide inhibited the oxidation of succinic acid and favored the oxidation of NADH, a carrier of electrons, which the authors say normalizes energy production in cardiomyocytes [15]. Mitochondria are the organelles that make ATP, the cell's energy currency, and a shift in which fuel they burn can matter more than raw oxygen supply. These are review-level descriptions, and the underlying experiments are not reported in full in the review.
Getting into cells: transporter docking and tissue targeting
For a peptide to act inside a cell, it has to cross the membrane, and Cardiogen is predicted to use nutrient transporters to get in. Transporters are membrane proteins that move amino acids and small peptides across the barrier. The LAT family carries large neutral amino acids, and the PEPT family carries di- and tripeptides, the two- and three-amino-acid products of protein digestion.
A 2023 docking study modeled 26 biologically active short peptides against LAT1, LAT2 and PEPT1 [9]. Docking is a computer method that scores how well a molecule fits a protein pocket, not a measurement of transport. The authors found that the binding sites were large enough for di-, tri- and tetrapeptides, and that Cardiogen scored among the strongest ligands for all three transporters [9].
A 2022 review of the same transporter families notes that PEPT carriers move mainly di- and tripeptides, while LAT1 can handle some short peptides, and argues that this route could explain why short peptides act on specific tissues [11]. The gap is obvious: neither paper reports a transport assay for Cardiogen in heart cells, so the transporter story remains a plausible delivery model rather than a demonstrated one [9][11].
What has been studied in humans
No peer-reviewed human trial of Cardiogen appears in PubMed or ClinicalTrials.gov as of October 23, 2026. The 2026 review describes only cell and animal experiments on Cardiogen [15]. A 2020 conference paper on rat stress says clinical studies have shown improved myocardial contractile function in patients with coronary heart disease, but it cites no trial and gives no data [7]. The only human cells in the indexed record are cultured prostate fibroblasts taken from human prostate tissue and aged in the dish by repeated passaging [4].
That 2010 study tested three short peptides, T-32, T-38 and Cardiogen, on human prostate fibroblasts, the main support cells of the prostate's microenvironment [4]. The readout was confocal laser microscopy of three signaling proteins: CXCL12, a chemokine that guides migrating cells; WEDC1, a factor named in the paper; and ghrelin, the stomach hormone that also acts in other tissues. All three peptides raised the expression of the three markers, whose synthesis falls in senescent cultures, and the response in seven-passage-old cultures tended to exceed that of one-passage young controls [4].
The ranking matters. T-38 was the most active of the three, so the result supports a class effect more than a Cardiogen-specific one [4]. It also says nothing about heart tissue, absorption, or what happens in a living human. A first-in-human study would need pharmacokinetics, the measurement of how much peptide reaches the blood and for how long, and a safety review that no source reviewed reports.
Lab and animal studies
Preclinical means work in cells, tissue or animals before a treatment reaches human testing, and the indexed Cardiogen record is entirely preclinical. The 2006 study set the pattern: four synthetic peptides, four tissues and two ages, with 0.05 nanograms per milliliter of each peptide added to organotypic cultures [1]. The readout was explant growth against control, and each peptide acted on its matching tissue in both young and old animals [1]. The design was a screen rather than a dose-response study, so it shows tissue preference without establishing potency.
The heart cultures received the most follow-up. In myocardium explants from 3-month-old and 24-month-old rats, Cardiogen at 10^-12 molar increased proliferation, and immunohistochemistry showed less p53, the tumor-suppressor protein that can trigger apoptosis [2]. A 2022 study measured the effect in the same culture system and reported a 24 percent increase in myocardial explant area and a 20 percent increase in vessel explant area at 0.05 nanograms per milliliter, with 17 to 20 samples per tissue and a significant difference from control [8]. The 2026 review adds that PCNA, a marker of dividing cells, covered more area in treated explants, while p53 covered less [15].
The coronary-ligation experiments are the strongest in vivo result in the review. In rats with a tied-off coronary artery, first-day mortality was 45 percent in controls and 15 percent in treated animals, necrotic zones in the heart were smaller, and the enzymes creatine phosphokinase and lactate dehydrogenase stayed in their normal range [15]. The review reads the result as preservation of cardiomyocyte viability and structure. It does not give the dose, the number of animals or the randomization method.
The adrenaline and arrhythmia models add functional data. In adrenaline-induced myocardial dystrophy, treatment lowered lipid peroxidation, reduced lactate dehydrogenase activity, kept glycogen at control levels and reduced the area of necrobiotic damage [15]. In a calcium chloride arrhythmia model, 0.2 micrograms per kilogram was the most effective dose, 0.2 and 0.5 micrograms per kilogram normalized heart rate, ventricular fibrillation was less frequent and sinus rhythm returned more often [15]. These are rat doses from the cited experiments, not human doses.
The tumor experiment is a separate branch. In senescent rats carrying M-1 sarcoma, Cardiogen slowed tumor growth in a dose-dependent way, and the effect came with hemorrhagic necrosis inside the tumor and more apoptotic tumor cells [3]. The authors used the proliferative activity data to argue that the peptide acted through the tumor's blood vessels rather than by killing tumor cells directly [3]. The abstract reports no dose and no survival analysis. The finding has not been followed by a second laboratory in the sources reviewed.
The mechanism work is laboratory-based and split between structural biology and cell culture. Mouse embryonic fibroblasts expressed two to five times more actin, tubulin and vimentin and two to three times more lamins A and C under the peptide [5]. A fluorescence study found that Cardiogen bound histones H1, H2B, H3 and H4 at their N-terminal tails, which the authors proposed as an epigenetic route to changes in gene activity [6]. A docking study placed the peptide among the best-fitting ligands for three nutrient transporters, LAT1, LAT2 and PEPT1, but measured binding in a computer model rather than in cells [9].
Research in detail
Organotypic tissue culture experiment with four synthetic peptides · Heart, lung, prostate and pancreas explants from 3-week-old and 18-month-old rats
Each peptide, Cardiogen among them, stimulated growth in its matching tissue at 0.05 nanograms per milliliter in both age groups.
Evidence scope: Abstract only; the abstract gives no group sizes, no statistics and no values per peptide, and it does not report replication.
Organotypic myocardium culture with amino acids and the tetrapeptide · Myocardium explants from 3-month-old and 24-month-old rats
Cardiogen at 10^-12 molar strongly stimulated proliferation in both age groups and lowered p53 protein expression, while only 7 of 20 amino acids were active in young tissue and 2 in old tissue.
Evidence scope: Abstract only; no group sizes, dose-response or statistics beyond the direction of the p53 change, and the abstract does not report replication.
Transplanted tumor experiment with graded peptide injections · Senescent rats carrying M-1 sarcoma
Cardiogen inhibited tumor growth in a dose-dependent way, with hemorrhagic necrosis and higher tumor-cell apoptosis; proliferative activity showed the effect was not a direct cytostatic action on tumor cells.
Evidence scope: Abstract only; dose levels, group sizes and survival data are not reported, and the model is a transplanted rat sarcoma.
Human cell culture with confocal microscopy of signaling markers · Human prostate fibroblasts at early and late passages, treated with T-32, T-38 or Cardiogen
All three peptides raised CXCL12, WEDC1 and ghrelin expression in senescent cultures, with late-passage responses tending to exceed young controls; T-38 was the most active.
Evidence scope: Abstract only; concentrations and sample numbers are not given, the cells are prostate rather than heart, and no functional endpoint was measured.
Protein expression measurement in cultured fibroblasts · Mouse embryonic fibroblasts
Cardiogen raised actin, tubulin and vimentin synthesis by two to five times and lamins A and C by two to three times.
Evidence scope: Abstract only; the paper reports no dose-response, the link from protein changes to survival is proposed rather than tested, and the cells are mouse embryonic fibroblasts.
Fluorescence quenching binding assay with plant histones and synthetic DNA · FITC-labeled wheat histones H1, H2B, H3 and H4, and deoxyribooligonucleotide complexes
Cardiogen bound all four histones at their N-terminal regions, and binding depended on histone type, peptide structure and oligonucleotide composition.
Evidence scope: Abstract only; plant histones and synthetic DNA, with no human chromatin and no transcriptional readout.
Adrenaline-induced stress experiment in rats with four groups · Male white rats, 200-250 g, in four groups of 16
In stressed rats, Cardiogen kept heart rate at control levels and reduced arrhythmia. Adrenal weight rose 67 percent versus control, which the authors read as a compensatory response; they also report a stress-related fall in heart and spleen weight.
Evidence scope: Full text read; 16 rats per group, one study, and some comparisons are reported only as trends.
Organotypic explant culture with peptide treatment · Heart and vessel explants from 3-month-old rats, with 17 to 20 samples per tissue
Cardiogen at 0.05 nanograms per milliliter raised myocardial explant growth by 24 plus or minus 3 percent and vessel explant growth by 20 plus or minus 3 percent, both significant.
Evidence scope: Full text read; Russian-language paper; the measured endpoint is explant area, and the paper reports no in vivo experiment.
History and where it stands today
Cardiogen moved from a four-tissue culture screen in 2006 to a small body of heart experiments, a 2026 review and an unchanged drug-regulatory position.
- 2006Zakutskii, Chalisova and colleagues report Cardiogen among four synthetic peptides that stimulated growth in matching organotypic cultures from young and old rats, including heart tissue at 0.05 nanograms per milliliter [1].
- 2009In heart explants from 3-month-old and 24-month-old rats, Cardiogen at 10^-12 molar raised proliferation and lowered p53, which the authors read as an anti-apoptotic effect [2].
- 2009Another 2009 study reports dose-dependent inhibition of M-1 sarcoma growth in senescent rats, with hemorrhagic necrosis and more tumor-cell apoptosis and no direct cytostatic effect [3].
- 2010Human prostate fibroblasts aged in culture respond to Cardiogen with higher CXCL12, WEDC1 and ghrelin expression, though another peptide in the panel, T-38, is the most active of the three tested [4].
- 2012 and 2013Mouse embryonic fibroblasts raise actin, tubulin, vimentin and lamin synthesis under Cardiogen [5], and a biochemistry study shows the peptide binds histones H1, H2B, H3 and H4 [6].
- 2020 to 2022A rat study of adrenaline-induced stress reports that Cardiogen brought heart rate back toward control and reduced arrhythmia, with adrenal weight rising, which the authors read as a compensatory response [7], and a 2022 explant study measures a 24 percent rise in myocardial growth and a 20 percent rise in vessel growth [8].
- 2023Docking work places Cardiogen among the strongest short-peptide ligands for the LAT1, LAT2 and PEPT1 transporters, a computational delivery hypothesis [9].
- 2026A review in Advances in Gerontology gathers the heart experiments, reports 15 percent first-day mortality after coronary ligation against 45 percent in controls, and calls the peptide cardioprotective in preclinical models [15].
- October 2026As of October 2026, Cardiogen remains a preclinical peptide in the indexed literature with no registered trial; WADA's 2026 list does not name it, and S0 covers substances with no governmental approval for human therapeutic use [13]. The NCAA 2026-27 list does not name it either, and its peptide-hormone class carries a catch-all for related substances, as the NCAA page explains [14].
How it compares with related peptides
Bronchogen is the lung-directed peptide from the same Saint Petersburg research program and was tested beside Cardiogen in the 2006 four-tissue experiment, where each peptide acted on its matching tissue [1]. Cardiogen's later work followed heart-muscle energetics and infarction, while bronchogen was tested on lung tissue in that panel [1]. The two share a design logic, a short synthetic chain aimed at one organ, but they diverged into different organ literatures.
Prostamax is the prostate-directed member of the same research program and appeared in the same 2006 panel of four peptides and four tissues [1]. Cardiogen also has human prostate-cell data, but those experiments used prostate fibroblasts as a model of cellular aging, not as a target organ [4]. The comparison shows how the series divided labor: one peptide per tissue, with Cardiogen carrying the cardiac experiments.
Pancragen is the pancreas-directed member of the same four-peptide set and was tested in the same organotypic screen [1]. Later work gave Pancragen to old rhesus monkeys and reported faster glucose disappearance and normalized insulin and C-peptide responses, so its literature moved toward pancreatic endocrine function [16]. Cardiogen's studies stayed on the heart, which makes the pair a clean example of how the series divided its organ targets.
Side effects and safety signals
The indexed safety record of Cardiogen rests on animal experiments, and no peer-reviewed human safety data are available.
- No peer-reviewed human tolerability data are available: the 2026 review covers preclinical experiments only, so no adverse-event rate can be given for any dose [15].
- In rats with a ligated coronary artery, first-day mortality was 15 percent in the treated group against 45 percent in controls, and the review does not report a toxicity signal in that experiment [15].
- In the adrenaline-dystrophy model, treatment lowered lipid peroxidation and lactate dehydrogenase activity and preserved glycogen, changes the review reads as protection of the muscle rather than harm [15].
- In the calcium chloride arrhythmia model, 0.2 micrograms per kilogram was the most effective dose and 0.2 and 0.5 micrograms per kilogram normalized heart rate; the review gives no safety margin and no toxicology [15].
- The M-1 sarcoma study found hemorrhagic necrosis inside the tumor, a local effect on tumor blood vessels, and the abstract gives no dose and no systemic toxicity data [3].
- The 2022 review asserts that the short peptides it discusses cause no allergic reactions and no side effects, a claim that no human trial of Cardiogen supports [10].
- Histone binding was measured with wheat proteins, so it says nothing about immune recognition or off-target gene effects in humans [6].
- Identity and purity are practical questions for a peptide this short, because one wrong residue makes a different molecule; the guide to reading a peptide COA explains what a certificate should show.
The future: what's next for Cardiogen
No Cardiogen trial is registered. A ClinicalTrials.gov search on October 23, 2026 returned no study of the peptide, and the records that match the search term are unrelated cardiac studies and a rubidium-82 imaging product. The same literature search returned no peer-reviewed clinical report. The next human data would have to come from a sponsor filing a first-in-human study, and no such filing appears in the sources reviewed.
No regulatory decision is pending on a calendar. The sources reviewed show no FDA submission or advisory committee item for Cardiogen, and the 2026 WADA and NCAA lists leave it to catch-all classes rather than naming it [13][14]. A 503A or 503B compounding decision would be a separate track from drug approval, and none is scheduled in the documents reviewed.
The 2026 review concludes that peptide preparations are promising for prevention and correction of age-related cardiovascular dysfunction, based on the preclinical results [15]. A next step would be a first-in-human study with pharmacokinetic measurements, but no sponsor has announced one. The transporter work adds a delivery question, because a docking score still needs a transport assay in heart cells [9]. A formulation that reaches the heart reliably would make any future trial easier to interpret.
- Which protein or DNA structure explains the gene-expression and mitochondrial effects remains unidentified in the sources reviewed [6][15].
- Whether the survival benefit after coronary ligation reproduces in a second laboratory and in a larger animal species is untested in the sources reviewed [15].
- How much Cardiogen reaches the heart after an injection, and by which transporter, has not been measured in either transporter paper [9][11].
- Whether the effect on tumor blood vessels carries any risk in humans is unknown, and no source reviewed reports a repeat of the sarcoma work [3].
- Whether a four-amino-acid peptide can be manufactured and controlled tightly enough for a clinical trial is a practical question for any sponsor.